Soligenix (NASDAQ:SNGX) shares added almost 35% before the opening bell on Tuesday after it revealed its novel vaccine provided 100% protection against two deadly infections in non-human primate models.
The company said that its single-vial bivalent vaccine demonstrated simultaneous protection against Sudan ebolavirus and Marburg Marburgvirus, two conditions for which there are no approved vaccines or therapeutics, in the preclinical evaluation.
The preclinical efficacy of the vaccine against both viruses was published in a paper in the medical journal Vaccine.
“Our combined vaccine platform includes three major components: a robust protein manufacturing process that has been demonstrated on multiple protein antigens, a novel nano-emulsion adjuvant which induces broad immunity and a formulation procedure which enables thermostabilization of the combination of adjuvant and antigens in a single vial," Soligenix (NASDAQ:SNGX) chief scientific officer Dr. Oreola Donini said in a statement.
“The ability to package the vaccine candidates in a single vial further adds to their developability, whether as a multivalent or individual monovalent vaccine, particularly against Marburg marburgvirus and Sudan ebolavirus where there are currently no available vaccines."
Shares of Soligenix (NASDAQ:SNGX) were up 34.7% at US$1.02 on the news.